Ten-year costs of cardiovascular disease in genetically verified familial hypercholesterolaemia compared with age- and sex-matched controls - Takeaways - MDSpire

Ten-year costs of cardiovascular disease in genetically verified familial hypercholesterolaemia compared with age- and sex-matched controls

  • By

  • Torbjørn Wisløff

  • Liv J Mundal

  • Jannicke Igland

  • Karianne Svendsen

  • Martin Prøven Bogsrud

  • Ivar Sønbø Kristiansen

  • Kjetil Retterstøl

  • September 23, 2025

  • 0 min

Share

  • 1

    Patients with genetically verified familial hypercholesterolaemia (FH) incurred significantly higher cardiovascular disease costs than matched controls.

  • 2

    During 2010-2019, FH patients had average CVD-related hospital costs of €3911 and pharmaceutical costs of €6119 per person.

  • 3

    Costs for prescription drugs in the FH population doubled over the study period, largely due to new treatment options.

  • 4

    FH patients experienced about three times higher hospital costs and over ten times higher pharmaceutical costs compared to controls.

  • 5

    The study highlights the economic burden of FH on healthcare resources, emphasizing the need for targeted treatment strategies.

Original Source(s)

Ten-year costs of cardiovascular disease in genetically verified familial hypercholesterolaemia compared with age- and sex-matched controls

  • by Torbjørn Wisløff, Liv J Mundal, Jannicke Igland, Karianne Svendsen, Martin Prøven Bogsrud, Ivar Sønbø Kristiansen, Kjetil Retterstøl

  • September 23, 2025

Related Content

Multicenter development and validation of machine-learning risk models to predict procedural complete revascularization and in-hospital heart failure in STEMI patients treated with primary PCI

Tirofiban After Tenecteplase in Stroke

Adjunctive tirofiban was linked to higher rates of positive 90-day outcomes in acute ischemic stroke.

Influence of nursing cardiac rehabilitation on cardiac function and quality of life in patients with coronary heart disease after percutaneous coronary intervention